Precision BioSciences, Inc.

DTIL Healthcare Biotechnology

Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.77 0.40 −6.48%
Market cap
$170.3M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
1/9
Altman Z
−4.31
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
94.40 64.33 115.68 193.67 105.56 161.75 199.11 136.36 94.99 118.74
Total non-current assets
— 8.35 22.93 41.56 44.59 49.74 39.06 23.42 41.40 35.68
Total Assets
98.41 72.68 138.60 235.23 150.16 211.50 238.17 159.78 136.39 154.42
Total current liabilities
8.34 9.20 14.08 26.93 42.83 35.98 59.66 49.99 14.98 8.91
Total non-current liabilities
— 89.85 84.57 69.99 62.90 84.35 118.07 90.93 65.02 53.26
Total liabilities
103.16 99.05 98.64 96.92 105.73 120.33 177.74 140.92 80.00 62.17
Common Equity (Total)
(4.75) (26.37) 39.96 138.31 44.43 91.17 60.43 18.86 56.39 92.25
Shareholders Equity (Total)
(4.75) (26.37) 39.96 138.31 44.43 91.17 60.43 18.86 56.39 92.25
Total Debt
— — — — 8.59 2.48 22.22 — 22.32 22.40

Show all line items

In millions of $ except per-share values · columns are period end dates